Catalog No.
DHC85102
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11049
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IMGN-529, K7153A-SMCC-DM1, K7153A, CAS: 1622327-39-2
Clone ID
Naratuximab
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models, PMID: 28753442
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies, PMID: 29323537
EHA 2021 Virtual Congress, PMID: 34153268
In the spotlight: a novel CD37 antibody-drug conjugate, PMID: 24235129
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies, PMID: 24002446
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study, PMID: 29453628
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model, PMID: 24445867
For research use only. Not for human or drug use.
